TrialJournal of addiction medicine

Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study.

Kent Hoffman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.